ISSUE 1556
| The full article is available to subscribers | Subscriber Login |
The FDA has approved elagolix (Orilissa – AbbVie), an oral gonadotropin-releasing hormone (GnRH) antagonist, for management of moderate to severe pain associated with endometriosis.
MECHANISM OF ACTION — Elagolix competitively binds to pituitary GnRH receptors, inhibiting GnRH signaling, reducing pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and decreasing ovarian production of estradiol and progesterone.
ENDOMETRIOSIS — Endometriosis is a chronic inflammatory condition that affects up to 10% of reproductive-age women. It is characterized by the presence of endometrial tissue outside the uterus, generally in the pelvic cavity, but distant migration can occur. Clinical features include dysmenorrhea, nonmenstrual pelvic pain, dyspareunia, and infertility. Pain associated with endometriosis adversely affects daily activities and
... more- Nafarelin for endometriosis. Med Lett Drugs Ther 1990; 32:81.
- L Muñoz-Hernando et al. Endometriosis: alternative methods of medical treatment. Int J Womens Health 2015; 7:595.
- S Ferrero et al. Current and emerging therapeutics for the management of endometriosis. Drugs 2018; 78:995.
- HS Taylor et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med 2017; 377:28.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017; September 18 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- FDA. Drug development and drug interactions: table of substrates, inhibitors and inducers. Available at www.fda.gov. Accessed September 13, 2018.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2018. Reprinted with permission by First Databank, Inc. All rights reserved. ©2018. www.fdbhealth.com/policies/drug-pricing-policy.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1556c
Electronic, downloadable article - $45
